vs
Side-by-side financial comparison of Hologic (HOLX) and HANOVER INSURANCE GROUP, INC. (THG). Click either name above to swap in a different company.
HANOVER INSURANCE GROUP, INC. is the larger business by last-quarter revenue ($1.7B vs $1.0B, roughly 1.6× Hologic). Hologic runs the higher net margin — 17.1% vs 11.0%, a 6.1% gap on every dollar of revenue. On growth, HANOVER INSURANCE GROUP, INC. posted the faster year-over-year revenue change (6.1% vs 2.5%). Over the past eight quarters, HANOVER INSURANCE GROUP, INC.'s revenue compounded faster (5.2% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
The Hanover Insurance Group, Inc. is an insurance company based in Worcester, Massachusetts. It was the original name of a property-liability insurance firm established in 1852, and it remained a publicly traded company under that name until the early 1990s, when it changed its name to Allmerica Property & Casualty Companies.
HOLX vs THG — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.7B |
| Net Profit | $179.1M | $186.8M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 11.1% |
| Net Margin | 17.1% | 11.0% |
| Revenue YoY | 2.5% | 6.1% |
| Net Profit YoY | -10.9% | 45.7% |
| EPS (diluted) | $0.79 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.0B | $1.7B | ||
| Q3 25 | $1.0B | $1.7B | ||
| Q2 25 | $1.0B | $1.7B | ||
| Q1 25 | $1.0B | $1.6B | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $988.0M | $1.6B | ||
| Q2 24 | $1.0B | $1.5B |
| Q1 26 | — | $186.8M | ||
| Q4 25 | $179.1M | $198.5M | ||
| Q3 25 | $187.2M | $178.7M | ||
| Q2 25 | $194.9M | $157.1M | ||
| Q1 25 | $-17.4M | $128.2M | ||
| Q4 24 | $201.0M | $167.9M | ||
| Q3 24 | $178.6M | $102.1M | ||
| Q2 24 | $194.5M | $40.5M |
| Q1 26 | — | — | ||
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — |
| Q1 26 | — | 11.1% | ||
| Q4 25 | 22.6% | 17.3% | ||
| Q3 25 | 22.6% | 14.9% | ||
| Q2 25 | 24.9% | 12.7% | ||
| Q1 25 | -0.7% | 11.6% | ||
| Q4 24 | 22.5% | 16.1% | ||
| Q3 24 | 23.3% | 9.6% | ||
| Q2 24 | 24.1% | 6.2% |
| Q1 26 | — | 11.0% | ||
| Q4 25 | 17.1% | 11.9% | ||
| Q3 25 | 17.8% | 10.7% | ||
| Q2 25 | 19.0% | 9.5% | ||
| Q1 25 | -1.7% | 8.0% | ||
| Q4 24 | 19.7% | 10.6% | ||
| Q3 24 | 18.1% | 6.5% | ||
| Q2 24 | 19.2% | 2.6% |
| Q1 26 | — | — | ||
| Q4 25 | $0.79 | $5.46 | ||
| Q3 25 | $0.84 | $4.90 | ||
| Q2 25 | $0.86 | $4.30 | ||
| Q1 25 | $-0.08 | $3.50 | ||
| Q4 24 | $0.87 | $4.60 | ||
| Q3 24 | $0.75 | $2.80 | ||
| Q2 24 | $0.82 | $1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $243.5M |
| Total DebtLower is stronger | $2.5B | $843.8M |
| Stockholders' EquityBook value | $5.2B | $3.0B |
| Total Assets | $9.2B | $16.5B |
| Debt / EquityLower = less leverage | 0.48× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $243.5M | ||
| Q4 25 | $2.4B | $1.1B | ||
| Q3 25 | $2.2B | $915.7M | ||
| Q2 25 | $1.9B | $244.1M | ||
| Q1 25 | $1.6B | $315.1M | ||
| Q4 24 | $2.0B | $435.5M | ||
| Q3 24 | $2.3B | $427.1M | ||
| Q2 24 | $2.4B | $337.6M |
| Q1 26 | — | $843.8M | ||
| Q4 25 | $2.5B | $843.3M | ||
| Q3 25 | $2.5B | $843.0M | ||
| Q2 25 | $2.5B | $347.8M | ||
| Q1 25 | $2.5B | $722.5M | ||
| Q4 24 | $2.5B | $722.3M | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $5.2B | $3.6B | ||
| Q3 25 | $5.0B | $3.4B | ||
| Q2 25 | $4.8B | $3.2B | ||
| Q1 25 | $4.6B | $3.0B | ||
| Q4 24 | $4.8B | $2.8B | ||
| Q3 24 | $5.1B | $2.9B | ||
| Q2 24 | $5.0B | $2.6B |
| Q1 26 | — | $16.5B | ||
| Q4 25 | $9.2B | $16.9B | ||
| Q3 25 | $9.0B | $16.8B | ||
| Q2 25 | $8.8B | $15.7B | ||
| Q1 25 | $8.5B | $15.5B | ||
| Q4 24 | $8.7B | $15.3B | ||
| Q3 24 | $9.2B | $15.4B | ||
| Q2 24 | $8.9B | $14.9B |
| Q1 26 | — | 0.28× | ||
| Q4 25 | 0.48× | 0.24× | ||
| Q3 25 | 0.50× | 0.25× | ||
| Q2 25 | 0.52× | 0.11× | ||
| Q1 25 | 0.55× | 0.24× | ||
| Q4 24 | 0.53× | 0.25× | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $378.2M | ||
| Q3 25 | $355.1M | $554.4M | ||
| Q2 25 | $343.3M | $206.6M | ||
| Q1 25 | $169.4M | $38.9M | ||
| Q4 24 | $189.3M | $213.5M | ||
| Q3 24 | $367.0M | $394.7M | ||
| Q2 24 | $405.8M | $139.5M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $377.0M | ||
| Q3 25 | $341.4M | $551.4M | ||
| Q2 25 | $330.5M | $204.9M | ||
| Q1 25 | $153.9M | $37.1M | ||
| Q4 24 | $172.5M | $210.5M | ||
| Q3 24 | $350.6M | $392.3M | ||
| Q2 24 | $385.3M | $137.3M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 22.6% | ||
| Q3 25 | 32.5% | 33.1% | ||
| Q2 25 | 32.3% | 12.4% | ||
| Q1 25 | 15.3% | 2.3% | ||
| Q4 24 | 16.9% | 13.3% | ||
| Q3 24 | 35.5% | 25.1% | ||
| Q2 24 | 38.1% | 8.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 0.1% | ||
| Q3 25 | 1.3% | 0.2% | ||
| Q2 25 | 1.3% | 0.1% | ||
| Q1 25 | 1.5% | 0.1% | ||
| Q4 24 | 1.6% | 0.2% | ||
| Q3 24 | 1.7% | 0.2% | ||
| Q2 24 | 2.0% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 1.91× | ||
| Q3 25 | 1.90× | 3.10× | ||
| Q2 25 | 1.76× | 1.32× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | 0.94× | 1.27× | ||
| Q3 24 | 2.05× | 3.87× | ||
| Q2 24 | 2.09× | 3.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
THG
| Premiums earned | $1.6B | 92% |
| Other | $124.6M | 7% |
| Fees and other income | $6.2M | 0% |
